Edition:
United Kingdom

Imv Inc (IMV.TO)

IMV.TO on Toronto Stock Exchange

7.51CAD
13 Dec 2018
Change (% chg)

-- (--)
Prev Close
$7.51
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
36,677
52-wk High
$9.49
52-wk Low
$5.18

Latest Key Developments (Source: Significant Developments)

IMV Inc Reaches Multiple Milestones In Advanced Ovarian Cancer Clinical Trial
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Imv Inc ::IMV INC. REACHES MULTIPLE MILESTONES IN ADVANCED OVARIAN CANCER CLINICAL TRIAL.IMV INC - EXPECTS TO RELEASE TOPLINE DATA FROM PHASE 1B ARMS OF STUDY BY END OF 2018.  Full Article

IMV Inc Reports Q1 Loss Per Share $0.7
Monday, 14 May 2018 

May 14 (Reuters) - Imv Inc ::IMV INC. (FORMERLY IMMUNOVACCINE INC.) ANNOUNCES Q1 2018 FINANCIAL RESULTS.IMV INC - QTRLY LOSS PER SHARE $0.7.  Full Article

Immunovaccine And Incyte Expand Clinical Collaboration
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE AND INCYTE EXPAND CLINICAL COLLABORATION EVALUATING COMBINATION IMMUNOTHERAPIES IN ADVANCED RECURRENT OVARIAN CANCER.IMMUNOVACCINE - COS PLAN TO ADD PHASE 2 COMPONENT TO ONGOING PHASE 1B STUDY OF DXP-SURVIVAC WITH INCYTE'S EPACADOSTAT AND LOW DOSE CYCLOPHOSPHAMIDE.IMMUNOVACCINE - PHASE 2 ARM OF STUDY TO BE CONDUCTED UNDER AMENDMENT TO EXISTING COLLABORATION, IN WHICH IMMUNOVACCINE & INCYTE ARE CO-FUNDING TRIAL.IMMUNOVACCINE INC - EXPECTS TO PROVIDE A CLINICAL UPDATE ON PHASE 1B PROGRAM IN FIRST HALF OF 2018.  Full Article

Immunovaccine announces positive clinical data from its collaborative combination immunotherapy trial in advanced ovarian cancer
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE ANNOUNCES POSITIVE CLINICAL DATA FROM ITS COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL IN ADVANCED OVARIAN CANCER.IMMUNOVACCINE INC - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL​ SHOW A 70% DISEASE CONTROL RATE DATA.IMMUNOVACCINE - EXPECTS TO PROVIDE CLINICAL UPDATE ON SECOND DOSING COHORT OF DPX-SURVIVAC IN FIRST HALF OF 2018.IMMUNOVACCINE - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL FOR DPX-SURVIVAC​DEMONSTRATE TOLERABLE SAFETY PROFILE.  Full Article

Immunovaccine reports qtrly loss per share of ‍$0.02​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Immunovaccine Inc :Immunovaccine announces third quarter 2017 financial results.Immunovaccine Inc qtrly loss per share ‍$0.02​.  Full Article

Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Immunovaccine Inc ::Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac in combination with Merck's checkpoint inhibitor Pembrolizumab in DLBCL.  Full Article